デフォルト表紙
市場調査レポート
商品コード
1425004

膀胱がん治療・診断市場:診断別、がんタイプ別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostic, By Cancer Type, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 289 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
膀胱がん治療・診断市場:診断別、がんタイプ別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2024年02月07日
発行: AnalystView Market Insights
ページ情報: 英文 289 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

膀胱がん治療・診断の市場規模は2022年に37億9,420万米ドルとなり、2023年から2030年にかけてCAGR 5.7%で拡大する見込みです。

膀胱がん治療・診断市場-市場力学

膀胱疾患と利用可能な治療法に対する認識の高まり、ヘルスケア支出の拡大、膀胱がんの負担の増大が市場需要を促進すると予測されます。

膀胱がん治療・診断市場は、膀胱疾患および利用可能な治療法に関する認知度の向上、医療支出の拡大、膀胱がんの負担の増大などの要因に後押しされ、急成長を遂げようとしています。例えば、2022年3月、世界膀胱がん患者連合は、膀胱がん啓発のための「Don't Go Red」テーマを宣言し、警告の徴候や症状に対する認識を高め、長期的な生存と生活の質の向上における早期発見の重要性を強調しました。さらに、膀胱がんの世界の有病率は上昇傾向にあり、世界がん観測統計2020によると、膀胱がんは世界で発生率の高いがんのトップ10に入っています。同報告書では、2020年に世界で新たに発生する膀胱がんの推定症例数は573,278例、前立腺がんの推定症例数は1,414,259例と記されています。この世界のがん罹患率の高さは、市場の重要な促進要因となっています。

膀胱がん治療・診断市場-主要インサイト

弊社のリサーチアナリストが分析したところによると、世界の膀胱がん治療・診断市場は、予測期間(2023~2030年)においてCAGR約5.7%で年間成長すると予測されています。

膀胱がん治療・診断市場は、膀胱疾患および利用可能な治療法に関する認知度の向上、医療支出の拡大、膀胱がんの負担の増大などを背景に、著しい速度で成長すると予測される

診断分野別では、膀胱鏡検査分野が2022年に最大の市場シェアを示すと予測されます。

がんの種類別では、移行細胞膀胱がんが2022年の主要セグメントでした。

地域別では、北米が2022年の主要収益源となる

膀胱がん治療・診断市場-セグメンテーション分析:

世界の膀胱がん治療・診断市場は、診断薬、がんタイプ別、地域別に区分されます。

診断に基づいて、市場は4つのセグメントに分けられます:膀胱鏡検査、膀胱超音波検査、尿検査、その他の診断。膀胱鏡検査分野は最も高い収益をあげており、予測期間中も主導的地位を維持すると予想されます。膀胱鏡検査は、尿道から挿入する特殊な内視鏡を使用して膀胱と尿道の内部を可視化する手順であり、予測期間中、調査対象市場の支配的なセグメントになると予測されています。この費用対効果の高い方法は、採用の増加、膀胱がんの有病率の上昇、主要市場プレイヤーによる製品発売が原動力となっています。

市場はがんタイプ別に3つのセグメントに分類される:移行細胞膀胱がん、扁平上皮膀胱がん、その他のがん種です。主に移行細胞膀胱がんの罹患率が高いことから、移行細胞膀胱がんセグメントは2030年までに世界の膀胱がん診断薬市場で大きなシェアを占めると予測されています。

膀胱がん治療・診断市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。北米は、がんの有病率の上昇により、予測期間中に市場を独占すると予想されています。例えば、米国がん協会の2022年1月の推計によると、米国では2022年に約81,180例の膀胱がんが新たに発生し、その内訳は男性61,700例、女性19,480例です。

膀胱がん治療・診断市場-競合情勢:

膀胱がん治療・診断の領域では、各社が革新的なアプローチの研究開発に熱心に取り組んでいます。治療薬では、膀胱がんの治療成績を向上させるための標的療法、特に免疫療法の進展が注目されています。ペムブロリズマブやアテゾリズマブなどの薬剤に代表される免疫チェックポイント阻害剤は、特定の膀胱がんタイプに対する承認を取得しており、現在進行中の調査によって治療選択肢のレパートリーが広がっています。さらに各社は、早期発見、予後、治療効果判定に役立つ新規バイオマーカーの探索に力を注いでいます。これらのバイオマーカーは、診断方法の改良と、より個別化された治療介入の指針となり、患者の転帰を改善し、膀胱がんの全体的な負担を軽減する可能性があります。この分野の企業は、早期診断から革新的な治療法に至るまで、膀胱がんに関連する課題に包括的に取り組み、患者のケアと生存率の向上を最終目標としています。

目次

第1章 膀胱がん治療・診断市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 膀胱がん治療・診断の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 膀胱がん治療・診断業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 膀胱がん治療・診断市場:COVID-19の影響分析

  • プレ新型コロナウイルス感染症の影響分析
  • ポスト新型コロナウイルス感染症の影響分析

第6章 膀胱がん治療・診断市場情勢

  • 膀胱がん治療・診断市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 膀胱がん治療・診断市場- 診断別

  • 概要
    • 診断別のセグメントシェア分析
    • 膀胱鏡検査
    • 膀胱超音波検査
    • 尿検査
    • その他の診断

第8章 膀胱がん治療・診断市場- がんタイプ別

  • 概要
    • がんタイプ別のセグメントシェア分析
    • 移行上皮性膀胱がん
    • 膀胱扁平上皮がん
    • その他のがんタイプ

第9章 膀胱がん治療・診断市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋(APAC)
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析- 膀胱がん治療・診断業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Lilly
    • F. Hoffmann-La Roche Ltd
    • GSK plc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Endo Pharmaceuticals Inc.
    • Johnson &Johnson Services

第11章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Diagnostics Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Diagnostics
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Cancer Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer Type
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
目次
Product Code: ANV2204

REPORT HIGHLIGHT

Bladder Cancer Therapeutics and Diagnostics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Bladder Cancer Therapeutics and Diagnostics Market- Market Dynamics

Increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer is expected to propel the market demand

The bladder cancer therapeutics and diagnostics market is poised for rapid growth, fueled by factors such as increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer. In March 2022, for example, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness of warning signs and symptoms, underscoring the importance of early detection in enhancing long-term survival and quality of life. Furthermore, the global prevalence of bladder cancer is on the rise, with bladder cancer ranking among the top 10 high-incidence cancers worldwide according to the Global Cancer Observatory Statistics 2020. In the same report, it was noted that in 2020, there were an estimated 573,278 new cases of bladder cancer and 1,414,259 cases of prostate cancer worldwide. This high incidence of cancer globally is a significant driver for the market.

Bladder Cancer Therapeutics and Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Bladder Cancer Therapeutics and Diagnostics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Bladder Cancer Therapeutics and Diagnostics Market is projected to grow at a significant rate driven by increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer

Based on Diagnostic, the Cystoscopy segment was predicted to show maximum market share in the year 2022

Based on Cancer Type, Transitional Cell Bladder Cancer was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Bladder Cancer Therapeutics and Diagnostics Market- Segmentation Analysis:

The Global Bladder Cancer Therapeutics and Diagnostics Market is segmented on the basis of Diagnostic, By Cancer Type, and Region.

Based on the Diagnostic, the market is divided into four segments: Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics. The Cystoscopy segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. Cystoscopy, a procedure for visualizing the interior of the bladder and urethra using a specialized endoscope inserted through the urethra, is projected to be the dominant segment in the studied market during the forecast period. This cost-effective method is driven by increasing adoption, the rising prevalence of bladder cancer, and product launches by key market players.

The market is categorized by Cancer Type into three segments: Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. The transitional cell bladder cancer segment is expected to hold a significant share of the global bladder cancer diagnostics market by 2030, primarily due to the high incidence of transitional cell bladder cancer.

Bladder Cancer Therapeutics and Diagnostics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period owing to the rising prevalence of cancer. For instance, as to the January 2022 estimates from the American Cancer Society, about 81,180 new cases of bladder cancer would occur in the United States year 2022, with 61,700 cases in men and 19,480 cases in women.

Bladder Cancer Therapeutics and Diagnostics Market- Competitive Landscape:

In the realm of bladder cancer therapeutics and diagnostics, companies are fervently researching and developing innovative approaches. In therapeutics, a notable focus is on the advancement of targeted therapies, particularly immunotherapies, to enhance bladder cancer treatment outcomes. Immune checkpoint inhibitors, exemplified by drugs like pembrolizumab and atezolizumab, have secured approvals for specific bladder cancer types, and ongoing investigations are expanding the repertoire of treatment options. Moreover, companies are dedicated to exploring novel biomarkers that can aid in early detection, prognosis, and treatment response assessment. These biomarkers can help refine diagnostic methods and guide more personalized therapeutic interventions, potentially improving patient outcomes and reducing the overall burden of bladder cancer. Companies in this space are committed to addressing the challenges associated with bladder cancer comprehensively, from early diagnosis to innovative treatment modalities, with the ultimate goal of enhancing patient care and survival rates.

Recent Developments:

In July 2022, the United States Food and Cancer Type Administration (FDA) agreed to review ImmunityBio's Biologics License Diagnostic (BLA) for N-803, which could benefit patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET KEY PLAYERS

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Lilly
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Endo Pharmaceuticals Inc.
  • Johnson & Johnson Services

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTIC

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Other Diagnostics

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bladder Cancer Therapeutics and Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Diagnostics
    • 2.1.2. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Country
    • 2.1.4. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Bladder Cancer Therapeutics and Diagnostics Key Market Trends

  • 3.1. Bladder Cancer Therapeutics and Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bladder Cancer Therapeutics and Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bladder Cancer Therapeutics and Diagnostics Market Opportunities
  • 3.4. Bladder Cancer Therapeutics and Diagnostics Market Future Trends

4. Bladder Cancer Therapeutics and Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bladder Cancer Therapeutics and Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bladder Cancer Therapeutics and Diagnostics Market Landscape

  • 6.1. Bladder Cancer Therapeutics and Diagnostics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bladder Cancer Therapeutics and Diagnostics Market - By Diagnostics

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnostics, 2022 & 2030 (%)
    • 7.1.2. Cystoscopy
    • 7.1.3. Bladder Ultrasound
    • 7.1.4. Urinalysis
    • 7.1.5. Other Diagnostics

8. Bladder Cancer Therapeutics and Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2022 & 2030 (%)
    • 8.1.2. Transitional Cell Bladder Cancer
    • 8.1.3. Squamous Cell Bladder Cancer
    • 8.1.4. Other Cancer Types

9. Bladder Cancer Therapeutics and Diagnostics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Bladder Cancer Therapeutics and Diagnostics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. AstraZeneca
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Lilly
    • 10.2.4. F. Hoffmann-La Roche Ltd
    • 10.2.5. GSK plc
    • 10.2.6. Novartis AG
    • 10.2.7. Pfizer Inc.
    • 10.2.8. Sanofi
    • 10.2.9. Endo Pharmaceuticals Inc.
    • 10.2.10. Johnson & Johnson Services

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us